Clinical Trials | April 30, 2026
Pfizer drug delivers breakthrough in late-stage blood cancer trial
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Health innovations are viewed more positively than food and agricultural technologies
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
The product is approved as bioequivalent to Xigduo XR for the indications outlined in the reference drug’s labelling
The system is powered by BrainSense technology, which has received approval from USFDA
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
